GlassScriptPhysician profile
Merrie A Cherry
NPI 1336287762
$39,327.56
in general payments reported to CMS, 2019-2025
22 companies · $27K in 2025
The $27K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $608 · 2021: $2,010 · 2022: $2,489 · 2023: $3,409 · 2024: $3,687 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $12K · Consulting Fee: $6,800 · Travel and Lodging: $2,616 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,000.00 |
| Food and Beverage | $11,541.18 |
| Consulting Fee | $6,800.00 |
| Travel and Lodging | $2,615.87 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24,822.07 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $2,052.02 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,028.50 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,987.26 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,902.74 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,658.18 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,488.75 | 2020-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $631.20 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $583.04 | 2024-2025 | Cobenfy |
| Indivior INC. | $466.58 | 2020-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $263.19 | 2022-2025 | Trintellix |
| Tris Pharma INC | $247.86 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $193.16 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $188.77 | 2023-2025 | Azstarys |
| Noven Therapeutics, LLC | $153.93 | 2021-2025 | Xelstrym, Secuado |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $141.64 | 2019-2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $139.50 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $131.31 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $85.55 | 2024-2025 | Auvelity |
| Allergan, INC. | $64.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $60.96 | 2021-2022 | |
| Eisai INC. | $36.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merrie Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.